Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nerandomilast - Boehringer Ingelheim

Next Previous
X
Search
Drug Profile

Nerandomilast - Boehringer Ingelheim

Alternative Names: BI-1015550

Latest Information Update: 10 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class 2 ring heterocyclic compounds; Alcohols; Amines; Anti-inflammatories; Antifibrotics; Chlorinated hydrocarbons; Cyclobutanes; Piperidines; Pyrimidines; Small molecules; Thiophenes
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic pulmonary fibrosis; Interstitial lung diseases

Most Recent Events

  • 06 Feb 2025 Boehringer Ingelheim plans a phase III SARD-ILD for Interstitial lung diseases in Australia, Austria, China, France, Germany, Italy, Japan, South Korea, Mexico, Netherlands, Norway, Puerto Rico, Spain, Switzerland, United Kingdom and USA in March 2025 (NCT06806592)
  • 17 Dec 2024 Boehringer Ingelheim completes a phase III trial in Idiopathic pulmonary fibrosis in the US, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, New Zealand, Norway, Puerto Rico, Poland, Portugal, Singapore, Spain, South Africa, Sweden, Switzerland, Taiwan, Thailand and the UK (PO) (NCT05321069)
  • 22 Nov 2024 Boehringer Ingelheim completes a phase I Bioavailability trial for two formulations of Nerandomilast (In volunteers, In adults) in Germany (PO) (NCT06624072) (EudraCT-2024-511245-18-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top